Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation

M. L. Donato, A. Aleman, R. E. Champlin, R. M. Saliba, J. T. Wharton, T. W. Burke, D. C. Bodurka, M. W. Bevers, C. F. Levenback, J. K. Wolf, R. C. Bast, R. S. Freedman, C. Ippoliti, M. Brewer, J. L. Gajewski, D. M. Gershenson

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The purpose of this study was to identify characteristics significant to survival and progression-free survival in patients with advanced ovarian cancer receiving high-dose chemotherapy. In all, 96 patients received autologous stem cell transplantation. Regimens included paclitaxel with carboplatin (PC), topotecan, melphalan, cyclophosphamide (TMC) and cyclophosphamide, BCNU, thiotepa (CBT). At the time of transplantation, 43% of patients were in clinical CR, 34% were in clinical PR, 18% had progressive disease and 5% had stable disease. There were no treatment-related deaths. The 6-year survival by Kaplan-Meier was 38%. For patients who received transplantation for remission consolidation, the 6-year survival was 53% with a PFS of 29%. On univariate analysis, the CBT regimen, clear cell histology and disease status other than CR prior to treatment were statistically significant adverse prognostic factors. This analysis has demonstrated that patients in clinical remission are most likely to benefit from autologous transplantation, with the exception of patients with clear cell histology. The TMC combination appeared to be superior to the PC and CBT combinations. Comparative studies of different consolidation approaches will be necessary to determine if autologous transplantation is the preferred treatment for this patient population.

Original languageEnglish (US)
Pages (from-to)1219-1224
Number of pages6
JournalBone Marrow Transplantation
Volume33
Issue number12
DOIs
StatePublished - Jun 2004
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Carcinoma
Cyclophosphamide
Drug Therapy
Thiotepa
Carmustine
Topotecan
Melphalan
Autologous Transplantation
Carboplatin
Paclitaxel
Survival
Histology
Transplantation
Ovarian Neoplasms
Disease-Free Survival
Therapeutics
Population

Keywords

  • High-dose chemotherapy
  • Ovarian cancer
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Donato, M. L., Aleman, A., Champlin, R. E., Saliba, R. M., Wharton, J. T., Burke, T. W., ... Gershenson, D. M. (2004). Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplantation, 33(12), 1219-1224. https://doi.org/10.1038/sj.bmt.1704473

Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. / Donato, M. L.; Aleman, A.; Champlin, R. E.; Saliba, R. M.; Wharton, J. T.; Burke, T. W.; Bodurka, D. C.; Bevers, M. W.; Levenback, C. F.; Wolf, J. K.; Bast, R. C.; Freedman, R. S.; Ippoliti, C.; Brewer, M.; Gajewski, J. L.; Gershenson, D. M.

In: Bone Marrow Transplantation, Vol. 33, No. 12, 06.2004, p. 1219-1224.

Research output: Contribution to journalArticle

Donato, ML, Aleman, A, Champlin, RE, Saliba, RM, Wharton, JT, Burke, TW, Bodurka, DC, Bevers, MW, Levenback, CF, Wolf, JK, Bast, RC, Freedman, RS, Ippoliti, C, Brewer, M, Gajewski, JL & Gershenson, DM 2004, 'Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation', Bone Marrow Transplantation, vol. 33, no. 12, pp. 1219-1224. https://doi.org/10.1038/sj.bmt.1704473
Donato, M. L. ; Aleman, A. ; Champlin, R. E. ; Saliba, R. M. ; Wharton, J. T. ; Burke, T. W. ; Bodurka, D. C. ; Bevers, M. W. ; Levenback, C. F. ; Wolf, J. K. ; Bast, R. C. ; Freedman, R. S. ; Ippoliti, C. ; Brewer, M. ; Gajewski, J. L. ; Gershenson, D. M. / Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. In: Bone Marrow Transplantation. 2004 ; Vol. 33, No. 12. pp. 1219-1224.
@article{9a7a9548604a489c9d2889280a96a79a,
title = "Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation",
abstract = "The purpose of this study was to identify characteristics significant to survival and progression-free survival in patients with advanced ovarian cancer receiving high-dose chemotherapy. In all, 96 patients received autologous stem cell transplantation. Regimens included paclitaxel with carboplatin (PC), topotecan, melphalan, cyclophosphamide (TMC) and cyclophosphamide, BCNU, thiotepa (CBT). At the time of transplantation, 43{\%} of patients were in clinical CR, 34{\%} were in clinical PR, 18{\%} had progressive disease and 5{\%} had stable disease. There were no treatment-related deaths. The 6-year survival by Kaplan-Meier was 38{\%}. For patients who received transplantation for remission consolidation, the 6-year survival was 53{\%} with a PFS of 29{\%}. On univariate analysis, the CBT regimen, clear cell histology and disease status other than CR prior to treatment were statistically significant adverse prognostic factors. This analysis has demonstrated that patients in clinical remission are most likely to benefit from autologous transplantation, with the exception of patients with clear cell histology. The TMC combination appeared to be superior to the PC and CBT combinations. Comparative studies of different consolidation approaches will be necessary to determine if autologous transplantation is the preferred treatment for this patient population.",
keywords = "High-dose chemotherapy, Ovarian cancer, Stem cell transplantation",
author = "Donato, {M. L.} and A. Aleman and Champlin, {R. E.} and Saliba, {R. M.} and Wharton, {J. T.} and Burke, {T. W.} and Bodurka, {D. C.} and Bevers, {M. W.} and Levenback, {C. F.} and Wolf, {J. K.} and Bast, {R. C.} and Freedman, {R. S.} and C. Ippoliti and M. Brewer and Gajewski, {J. L.} and Gershenson, {D. M.}",
year = "2004",
month = "6",
doi = "10.1038/sj.bmt.1704473",
language = "English (US)",
volume = "33",
pages = "1219--1224",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation

AU - Donato, M. L.

AU - Aleman, A.

AU - Champlin, R. E.

AU - Saliba, R. M.

AU - Wharton, J. T.

AU - Burke, T. W.

AU - Bodurka, D. C.

AU - Bevers, M. W.

AU - Levenback, C. F.

AU - Wolf, J. K.

AU - Bast, R. C.

AU - Freedman, R. S.

AU - Ippoliti, C.

AU - Brewer, M.

AU - Gajewski, J. L.

AU - Gershenson, D. M.

PY - 2004/6

Y1 - 2004/6

N2 - The purpose of this study was to identify characteristics significant to survival and progression-free survival in patients with advanced ovarian cancer receiving high-dose chemotherapy. In all, 96 patients received autologous stem cell transplantation. Regimens included paclitaxel with carboplatin (PC), topotecan, melphalan, cyclophosphamide (TMC) and cyclophosphamide, BCNU, thiotepa (CBT). At the time of transplantation, 43% of patients were in clinical CR, 34% were in clinical PR, 18% had progressive disease and 5% had stable disease. There were no treatment-related deaths. The 6-year survival by Kaplan-Meier was 38%. For patients who received transplantation for remission consolidation, the 6-year survival was 53% with a PFS of 29%. On univariate analysis, the CBT regimen, clear cell histology and disease status other than CR prior to treatment were statistically significant adverse prognostic factors. This analysis has demonstrated that patients in clinical remission are most likely to benefit from autologous transplantation, with the exception of patients with clear cell histology. The TMC combination appeared to be superior to the PC and CBT combinations. Comparative studies of different consolidation approaches will be necessary to determine if autologous transplantation is the preferred treatment for this patient population.

AB - The purpose of this study was to identify characteristics significant to survival and progression-free survival in patients with advanced ovarian cancer receiving high-dose chemotherapy. In all, 96 patients received autologous stem cell transplantation. Regimens included paclitaxel with carboplatin (PC), topotecan, melphalan, cyclophosphamide (TMC) and cyclophosphamide, BCNU, thiotepa (CBT). At the time of transplantation, 43% of patients were in clinical CR, 34% were in clinical PR, 18% had progressive disease and 5% had stable disease. There were no treatment-related deaths. The 6-year survival by Kaplan-Meier was 38%. For patients who received transplantation for remission consolidation, the 6-year survival was 53% with a PFS of 29%. On univariate analysis, the CBT regimen, clear cell histology and disease status other than CR prior to treatment were statistically significant adverse prognostic factors. This analysis has demonstrated that patients in clinical remission are most likely to benefit from autologous transplantation, with the exception of patients with clear cell histology. The TMC combination appeared to be superior to the PC and CBT combinations. Comparative studies of different consolidation approaches will be necessary to determine if autologous transplantation is the preferred treatment for this patient population.

KW - High-dose chemotherapy

KW - Ovarian cancer

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=3242715107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242715107&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704473

DO - 10.1038/sj.bmt.1704473

M3 - Article

VL - 33

SP - 1219

EP - 1224

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 12

ER -